Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Kisspeptin-10 and Melanotan I — mechanism, side effects, legal status, and pricing.
Kisspeptin-10 (KP-10) is the 10-amino-acid C-terminal fragment of kisspeptin (the KISS1 gene product, also called metastin) that retains full biological activity. It is an investigational signaling peptide that sits at the top of the reproductive axis and is studied for fertility, hypogonadism, and as a diagnostic challenge. It is not FDA-approved.
Kisspeptin-10
Melanotan I
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Kisspeptin-10
Melanotan I
COA corpus from Disclosed Labs — independently tested batches only.
Kisspeptin-10
50
COAs
99.6%
Avg purity
11
Labs
Melanotan I
50
COAs
99.7%
Avg purity
12
Labs
The foundational role of kisspeptin in reproduction was established by de Roux et al. (PNAS, 2003, PMID 12944565) and Seminara et al. (NEJM, 2003, PMID 14573733), who identified loss-of-function mutations in GPR54 causing hypogonadotropic hypogonadism. Dhillo et al. (JCEM, 2005) showed kisspeptin-54 stimulates LH, FSH, and testosterone in men; George et al. (JCEM, 2011, PMID 21632807) confirmed IV kisspeptin-10 boluses stimulate LH and increase pulse frequency in men. Young et al. (Neuroendocrinology, 2012, PMID 22377698) showed kisspeptin infusion restores pulsatile LH in patients with neurokinin B (TAC3/TACR3) signaling deficiencies. Abbara/Jayasena and colleagues (JCEM 2015, PMID 26192876; Hum Reprod 2017, PMID 28854728) demonstrated kisspeptin-54 can trigger oocyte maturation in IVF with very low OHSS rates. The kisspeptin receptor agonist MVT-602 has been in Phase 2 development for female HSDD. Grey-market SubQ use (~200 mcg 2x/week for libido or testosterone support) is not supported by controlled trials.
Key references
FDA-approved as Scenesse (Clinuvel, October 8, 2019) for increasing pain-free light exposure in adults with EPP, based on Phase III trials CUV039 and CUV040 showing more hours spent in sunlight without pain vs. placebo (Langendonk et al., NEJM, 2015; PMID 26132941). A randomized multicenter trial (Lim et al., JAMA Dermatology, 2015; PMID 25230094) also showed increased repigmentation when afamelanotide was combined with narrow-band UVB in vitiligo.
Key references
Kisspeptin-10 (Hormone) and Melanotan I (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing